Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HEMASURE FILING 510(K) BY YEAR-END FOR LEUKONET FILTER LEUKOCYTE REMOVAL SYSTEM; SEPRACOR SUBSIDIARY EXPECTS TO NET $15- $17 MIL. FROM INITIAL PUBLIC OFFERING

This article was originally published in The Gray Sheet

Executive Summary

HemaSure plans to file a 510(k) in the second half of 1994 for its lead product, the LeukoNet Filter for removing leukocytes from red blood cells and platelet concentrates, the Sepracor subsidiary notes in a March 10 registration statement with the Securities and Exchange Commission for an initial public offering.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002036

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel